Bio-Path Holdings
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4710 Bellaire Blvd Ste 210, Bellaire, Te...Phone Number
(832) 742-1357Website
www.biopathholdings.comRevenue
<$5 MillionStock Symbol
BPTHIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Bio-Path Holdings
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers.Explore more
Bio-Path Holdings Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bio-Path Holdings your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Bio-Path Holdings recently announced quarterly report
Bio-Path Holdings, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Bio-Path Holdings launches new products
Check out if Bio-Path Holdings is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Bio-Path Holdings
Click to see if Bio-Path Holdings had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Bio-Path Holdings has new funding data
Check if Bio-Path Holdings has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Bio-Path Holdings as Masked Content
Find 2 more new buyers
Compare Similar Companies to Bio-Path Holdings
Compare insights from companies similar to Bio-Path Holdings, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bio-Path Holdings
<$5M
1-10
Public
$7.2M
2007
CM
Chelsea McKinneySenior Administrative Assistant, To Vice President, Finance, Accounting & Administration
Company Profile Activity
Activity Insights
Bio-Path Holdings is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bio-Path Holdings is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bio-Path Holdings.
Bio-Path Holdings financials insights
Gather financial insights about Bio-Path Holdings, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Stock Offering
$3.1M
2025
Other Financing Round
$4M
Bio-Path Holdings Tech Stack
A closer look at the technologies used by Bio-Path Holdings
Most Recent Scoops
Project
Bio-Path Holdings has four drug products in development, including a Phase 2 clinical trial in AML, a Phase 1 clinical trial in solid tumors, a Phase 1 clinical trial in relapsed AML patients, and a drug candidate in final preclinical development that regulates five key cancer processes.
Product Development, Pharmaceuticals, Clinical Operations
Project
Bio-Path Holdings has reported significant research output through peer-reviewed papers and abstract posters at major industry meetings, leading to industry interest including potential pediatric programs and discussions with larger pharma companies.
Research & Development
Project
Bio-Path Holdings has developed D-Enablize, an advanced oligonucleotide therapeutic delivery system that allows systemic delivery of RNAi therapeutics throughout the body without toxicity. This patented technology enables the company to develop new products with potential for patenting.
Product Development, Research & Development, Pharmaceuticals
Project
Bio-Path Holdings has set several milestones for the next 12 months, including incorporating molecular markers in its Phase 2 AML trial, completing the fourth dosing cohort for BP 1002 in relapsed AML, finishing the last cohort of its solid tumor trial, and completing a preclinical study for type 2 diabetes treatment.
Research & Development, Pharmaceuticals, Clinical Operations
Project
Research & Development, Intellectual Property, Legal Affairs
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bio-Path Holdings
Sign Up For FreeTo access detailed company insights
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers.... Read More
